Search research articles
Contact Us
Filters
Showing results (181-190 of 265) with videos related to
Page
of 27
Sort By:
Journal of the American Academy of Dermatology
|
December 29, 2016
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
Kristian Reich, Craig Leonardi, Richard G Langley, et al.
Journal of Drugs in Dermatology : JDD
|
August 16, 2021
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2
Peter Foley, Kristian Reich, Andrew Blauvelt, et al.
Lancet (London, England)
|
May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A Papp, Richard G Langley, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 13, 2023
SARS-CoV-2 vaccination status and adverse events among patients with psoriasis-Data from the German Registries PsoBest and CoronaBest
María José Valencia López, Anna Meineke, Brigitte Stephan, et al.
The New England Journal of Medicine
|
April 23, 2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B Warren, Mark Lebwohl, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 23, 2024
SARS-CoV-2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest
María José Valencia López, Anna Meineke, Brigitte Stephan, et al.
Journal of Drugs in Dermatology : JDD
|
February 21, 2018
Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials
Neil H Shear, Carle Paul, Andrew Blauvelt, et al.
Dermatology (Basel, Switzerland)
|
August 8, 2008
Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus
Kristian Reich, Christopher Griffiths, Jonathan Barker, et al.
Journal of the American Academy of Dermatology
|
October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials
Kenneth B Gordon, Kim A Papp, Richard G Langley, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
January 8, 2014
German psoriasis registry PsoBest: objectives, methodology and baseline data
Matthias Augustin, Christina Spehr, Marc A Radtke, et al.
Page
of 27
Search research articles
Search
Showing results (181-190 of 265) with videos related to
Sort By:
Page
of 27
Journal of the American Academy of Dermatology
|
December 29, 2016
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
Kristian Reich, Craig Leonardi, Richard G Langley, et al.
Journal of Drugs in Dermatology : JDD
|
August 16, 2021
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2
Peter Foley, Kristian Reich, Andrew Blauvelt, et al.
Lancet (London, England)
|
May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A Papp, Richard G Langley, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 13, 2023
SARS-CoV-2 vaccination status and adverse events among patients with psoriasis-Data from the German Registries PsoBest and CoronaBest
María José Valencia López, Anna Meineke, Brigitte Stephan, et al.
The New England Journal of Medicine
|
April 23, 2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
Kristian Reich, Richard B Warren, Mark Lebwohl, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 23, 2024
SARS-CoV-2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest
María José Valencia López, Anna Meineke, Brigitte Stephan, et al.
Journal of Drugs in Dermatology : JDD
|
February 21, 2018
Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials
Neil H Shear, Carle Paul, Andrew Blauvelt, et al.
Dermatology (Basel, Switzerland)
|
August 8, 2008
Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus
Kristian Reich, Christopher Griffiths, Jonathan Barker, et al.
Journal of the American Academy of Dermatology
|
October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials
Kenneth B Gordon, Kim A Papp, Richard G Langley, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
January 8, 2014
German psoriasis registry PsoBest: objectives, methodology and baseline data
Matthias Augustin, Christina Spehr, Marc A Radtke, et al.
Page
of 27